- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
EGFR-targeted mesenchymal stem cells for enhanced tumor retention and inhibition (Section 19; Poster Board #24) - Mar 14, 2023 - Abstract #AACR2023AACR_2414; Biodistribution studies revealed a sixfold higher retention of functionalized MSCs when compared to unfunctionalized MSCs. These results demonstrate the potential for improved tumor targeting with EGFR-targeted MSCs.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
ADAM17 knockout NK or CAR NK cells augment antibody dependent cellular cytotoxicity (ADCC) and anti-tumor activity (Section 37; Poster Board #5) - Mar 14, 2023 - Abstract #AACR2023AACR_2271; Similarly, ADAM17 KO NK cells and ADAM17 KO CD70 CAR NK cells also showed enhanced cytotoxicity against 786-O tumor cells in the presence of anti-EGFR antibody, cetuximab...Taken together, we show ADAM17 KO NK or ADAM17 KO CAR NK cells demonstrate improved ADCC and ADAM17 KO can enhance in vivo anti-tumor activity of CISH/CBLB KO CD70 CAR NK cells against relevant tumor models. These data support the further exploration of ADAM17 gene knockout NK cells for clinical application and to improve efficacy of therapeutic antibodies in combination with adoptive transfer of engineered NK cells.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen, Stivarga (regorafenib) / Bayer
Trial primary completion date, Metastases: REVERCE II: Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer (clinicaltrials.gov) - Mar 14, 2023 P2, N=124, Recruiting, Practice-changing trials remain elusive, and the search continues to attempt optimization of the therapeutic ratio for these patients. Trial primary completion date: Feb 2023 --> Feb 2024
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Retrospective data, Review, Journal, Microsatellite instability, Metastases: Predictive and Prognostic Value of Oncogene Mutations and Microsatellite Instability in Locally-Advanced Rectal Cancer Treated with Neoadjuvant Radiation-Based Therapy: A Systematic Review and Meta-Analysis. (Pubmed Central) - Mar 11, 2023 This association was even more significant in patients not receiving cetuximab (summary OR = 2.17, 95% CI: 1.41-3.33) than in patients receiving cetuximab (summary OR = 0.89, 95% CI: 0.39-20.05)...Translating this finding into the clinic could improve the management of LARC patients. More data are needed to clarify the clinical impact of TP53, BRAF, PIK3CA, and SMAD4 mutations.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, RSL3 / Stanford University
Journal: Blocking EREG/GPX4 Sensitizes Head and Neck Cancer to Cetuximab through Ferroptosis Induction. (Pubmed Central) - Mar 11, 2023 This is illustrated by the reduction in cell survival, the alteration of cell metabolism associated with mitochondrial dysfunction and the initiation of ferroptosis characterized by lipid peroxidation, iron accumulation and the loss of GPX4. Combining ferroptosis inducers (RSL3 and metformin) with CTX drastically reduces the survival of HNSCC cells but also HNSCC patient-derived tumoroids; (4) The loss of EREG might be considered in clinical settings as a predictive biomarker for patients that might undergo ferroptosis in response to CTX and that might benefit the most from the combination of ferroptosis inducers and CTX.
- |||||||||| azenosertib (ZN-c3) / Zentalis Pharma
Enrollment open, Combination therapy, Metastases: ZN-c3 in Adult Participants With Metastatic Colorectal Cancer (clinicaltrials.gov) - Mar 10, 2023 P1/2, N=82, Recruiting, Combining ferroptosis inducers (RSL3 and metformin) with CTX drastically reduces the survival of HNSCC cells but also HNSCC patient-derived tumoroids; (4) The loss of EREG might be considered in clinical settings as a predictive biomarker for patients that might undergo ferroptosis in response to CTX and that might benefit the most from the combination of ferroptosis inducers and CTX. Not yet recruiting --> Recruiting
- |||||||||| monalizumab (IPH2201) / AstraZeneca, Innate, Imfinzi (durvalumab) / AstraZeneca
Enrollment closed, Trial completion date, IO biomarker, Metastases: A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors (clinicaltrials.gov) - Mar 9, 2023 P1/2, N=383, Active, not recruiting, The use of molecularly targeted agents in the neoadjuvant setting for locally advanced rectal cancer has an acceptable prognosis. Completed --> Active, not recruiting | Trial completion date: Oct 2021 --> Jun 2023
- |||||||||| etokimab (ANB020) / AnaptysBio, Erbitux (cetuximab) / Eli Lilly, EMD Serono
EGF is an important modulator of the release of the alarmin IL-33 by human keratinocytes () - Mar 4, 2023 - Abstract #ISID2023ISID_1243; The EGFR pathway is an important modulator of IL-33 release. A better understanding of the cellular events that leading to modulation of the alarmin IL-33 by EGF may provide novel therapeutic targets in atopic dermatitis.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: NKp46-specific single domain antibodies enable facile engineering of various potent NK cell engager formats. (Pubmed Central) - Mar 2, 2023 Herein, we describe the generation of potent NK cell engagers (NKCEs) based on single domain antibodies (sdAbs) specific for NKp46 harboring the humanized Fab version of Cetuximab for tumor targeting...By this means, killing capacities were further improved significantly. Hence, NKp46-specific sdAbs are versatile building blocks for the construction of different NKCE formats.
- |||||||||| Bavencio (avelumab) / EMD Serono, Pfizer, Erbitux (cetuximab) / Eli Lilly, EMD Serono
P2 data, Clinical Trial,Phase II, Journal, Tumor mutational burden, PD(L)-1 Biomarker, IO biomarker: Extensive molecular profiling of squamous cell anal carcinoma in a phase 2 trial population: Translational analyses of the "CARACAS" study. (Pubmed Central) - Mar 2, 2023 P2 Hence, NKp46-specific sdAbs are versatile building blocks for the construction of different NKCE formats. To our knowledge, TranslaCARACAS is the first study to document prognostic role of TMB and PD-L1 in advanced SCAC patients treated with immune checkpoint inhibitors.
- |||||||||| Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen, Takeda
Review, Journal, HEOR, Cost-effectiveness, Cost effectiveness, Metastases: Cost-effectiveness Analysis of Monoclonal Antibodies in the First-line Treatment of RAS Wild-type Metastatic Colorectal Cancer: A Systematic Review. (Pubmed Central) - Mar 2, 2023 This article examines molecular markers that can predict colorectal cancer prognosis. Although treatment with monoclonal antibodies has demonstrated efficacy in terms of life-years gained and progression-free survival, the most cost-effective treatment among monoclonal antibodies remains controversial; however, most of the studies that compared a monoclonal antibody
- |||||||||| PF-07284892 / Pfizer
Trial completion date, Trial primary completion date, Combination therapy, Metastases: PF-07284892 in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Mar 2, 2023 P1, N=196, Recruiting, Further prospective trials would be needed to confirm our results. Trial completion date: Feb 2027 --> Apr 2026 | Trial primary completion date: Feb 2026 --> Apr 2025
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD), Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Trial completion date, Metastases: PembroRad: Tolerance and Efficacy of Pembrolizumab or Cetuximab Combined With RT in Patients With Locally Advanced HNSCC (clinicaltrials.gov) - Feb 28, 2023 P2, N=133, Completed, A comparison of cetuximab, PARPi and combination applications showed the superiority of combined applications over single applications in all cell kinetic parameters used. Active, not recruiting --> Completed | Trial completion date: Oct 2023 --> Oct 2022
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Evaluation of Concomitant Systemic Treatment in Older Adults With Head and Neck Squamous Cell Carcinoma Undergoing Definitive Radiotherapy. (Pubmed Central) - Feb 27, 2023 The survival benefit of the chemoradiation group was present in patients up to age 80 years (65-69 years: HR, 0.52; 95% CI, 0.33-0.82; 70-79 years: HR, 0.60; 95% CI, 0.43-0.85), but was absent in patients aged 80 years or older (HR, 0.89; 95% CI, 0.56-1.41). In this cohort study of older adults with LA- HNSCC, chemoradiation, but not cetuximab-based bioradiotherapy, was associated with longer survival compared with radiotherapy alone.
- |||||||||| Imjudo (tremelimumab) / AstraZeneca, Pfizer, Imfinzi (durvalumab) / AstraZeneca
P3 data, Journal, PD(L)-1 Biomarker, IO biomarker, Metastases: Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study. (Pubmed Central) - Feb 27, 2023 In patients with PD-L1-high expression, OS was comparable between durvalumab and the EXTREME regimen. Durvalumab alone, and with tremelimumab, demonstrated durable responses and reduced TRAEs versus the EXTREME regimen in R/M HNSCC.
- |||||||||| Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer, Mektovi (binimetinib) / Ono Pharma, Pierre Fabre, Pfizer
Trial completion date, Metastases: ANCHOR-CRC: Encorafenib, Binimetinib and Cetuximab in Subjects With Previously Untreated BRAF-mutant ColoRectal Cancer (clinicaltrials.gov) - Feb 27, 2023 P2, N=95, Active, not recruiting, Trial completion date: Nov 2023 --> Sep 2025 | Trial primary completion date: Nov 2023 --> Sep 2025 Trial completion date: Oct 2022 --> Apr 2023
- |||||||||| utomilumab (PF-05082566) / Pfizer, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion date, Trial primary completion date, Metastases: Utomilumab, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Feb 27, 2023 P1, N=42, Active, not recruiting, Trial completion date: Oct 2022 --> Apr 2023 Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Dec 2023
|